DNA Company Profile and Key Details

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) closed at $10.10 USD, gaining $1.78 (21.39%) from the previous close of $8.32. The stock is currently mid-range between its 52-week high and low $5.00 and $17.58. With a market capitalization of about $574.06 million, Ginkgo Bioworks Holdings, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.56). Key stats such as the average daily volume over the past year has been around 1.03 million shares, trading with heavier-than-usual volume. Headquartered in Boston, MA, Ginkgo Bioworks Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jason Kelly, the company employs approximately 834 people and listed since April 19, 2021. Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming.

Short-term trend indicators are mixed aligned (SMA20 6.97%, SMA50 10.98%, SMA200 -2.17%). The stock’s 14-day RSI is 57.77 (neutral), while the ATR of 0.78 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -42.55% below its high and over 102.0% above its low. Average 10-day trading volume of 1.42 million shares is slightly above the 3-month average of 1.07 million, indicating heightened recent market interest.

Ginkgo Bioworks Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$7.93. This means the shares are trading below this model’s fair value.

Ginkgo Bioworks Holdings, Inc. generated EPS of -$6.23 over the past year. Five-year average earnings growth is -27.97%. The latest quarter delivered EPS of -$1.45. The next quarter is forecast at -$1.46. Next year's EPS is expected at $30.33. Analyst sentiment is bearish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $9.00. The high target offers 38.61% upside. The low target suggests -10.89% downside. The mean target is $11.50. This offers 13.86% upside. Ginkgo Bioworks Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 16.94%. The prior quarter beat by -23.61%. Over the last six quarters, Apple has recorded several small beats. These include 32.1% in August 08, 2024.

Ginkgo Bioworks Holdings, Inc. has 47.09 million shares outstanding. The public float is 37.81 million shares, elevated short interest at 14.63% of float. This equals 6.71 million shares. The short ratio is 4.24 days. Institutional investors hold 84.85% of the float. Insiders own 6.77%. Canton Barry holds 12.37 million shares, Shetty Reshma P. has 12.37 million shares and DEKKERS MARIJN E has 5.52 million shares. Over the past six months, insider transactions show net selling. They sold 28.94 thousand shares across 7 transactions.